Clinical trials: Docetaxel, completed
Hormone-Refractory Prostate Cancer
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate (Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone-refractory prostate cancer.
- Trial name
- NCT00151073
- Testing
- Zoledronic acid, Estramustine, Docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostatic Neoplasms, Castration-Resistant
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate…
- Trial name
- NCT02204072
- Testing
- BI 836845, Enzalutamide
- Where
- 27 sites in United States, Hong Kong and 6 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Gastro Oesophageal Cancer
A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
Whilst oxaliplatin and docetaxel have established activity in the treatment of advanced gastro-oesophageal cancer, their role, however, in the management of this disease remains unclear.
- Trial name
- ELECT (NCT01710592)
- Testing
- Epirubicin, Oxaliplatin, Capecitabine
- Where
- 6 sites in Ireland
- Volunteers
- 35 people
- Sponsor
- Cancer Trials Ireland
Sarcoma, Soft Tissue
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and docetaxel, to find out which treatment is better for people with sarcomas.
- Trial name
- NCT00142571
- Testing
- Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer
A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer
The purpose of this study is to attempt to find better tolerated doses and schedules of this highly effective combination chemotherapy regimen.
- Trial name
- NCT00214864
- Testing
- docetaxel, capecitabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Cancer Research Network
Prostate Cancer, Prostatic Neoplasms
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
To determine: Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate cancer. Group A - subjects who have not previously received chemotherapy Group B - sujects who have received prior chemotherapy…
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Cancer of the Prostate
- Trial name
- IPI-504-04 (NCT00564928)
- Testing
- IPI-504
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Squamous Cell Carcinoma, Carcinoma of Head/Neck
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects…
- Trial name
- NCT00139230
- Testing
- Taxotere, Cisplatin, 5-Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080665
- Testing
- docetaxel, imatinib mesylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer Female
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
This was an open-label, randomized controlled trial that aims to compare the efficacy and safety of the concurrent neoadjuvant chemotherapy with endocrine therapy and neoadjuvant chemotherapy alone in ER-positive, HER2-negative…
- Trial name
- NCT02980965
- Testing
- letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel, fluorouracil, epirubicin, cyclophosphamide, docetaxel
- Where
- China
- Volunteers
- 249 people
- Sponsor
- Fudan University
Head and Neck Squamous Cell Carcinoma
Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma
Nimotuzumab (hR3) is an humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01425736
- Testing
- Chemotherapy, Nimotuzumab and Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 91 people
- Sponsor
- Wei Guo
Breast Cancer
Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
This is a Phase 4, single-arm, open-label, multicenter study to assess the safety and efficacy of pertuzumab in combination with trastuzumab and docetaxel for the treatment of participants with human epidermal growth factor…
- Trial name
- NCT02445586
- Testing
- Docetaxel, Pertuzumab, Trastuzumab
- Where
- 9 sites in India
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Neutropenia
Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
Physicians are conducting a clinical trial for patients with advanced breast cancer. Breast cancer can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced.
- Trial name
- NCT00035594
- Testing
- pegfilgrastim
- Volunteers
- 928 people
- Sponsor
- Amgen
Advanced Solid Tumors, Adenocarcinoma of the Prostate
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
The purpose of this study is to evaluate the safety and tolerability of alisertib in combination with docetaxel as a treatment for participants with advanced solid tumors, including castration-resistant prostate cancer, who were…
- Trial name
- NCT01094288
- Testing
- Alisertib, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Salvage Ovarian FANG™ Vaccine + Carboplatinum
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with carboplatinum. All patients will have Vigil™ prepared and stored from ovarian tumor cells obtained at the time of primary surgical debulking.
- Trial name
- NCT01867086
- Testing
- Vigil™ Vaccine, Carboplatinum, Carboplatinum and Taxol
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gradalis, Inc.
Lung Cancer
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00073866
- Testing
- celecoxib, docetaxel, irinotecan hydrochloride
- Where
- 3 sites in United States
- Sponsor
- Northwestern University
Carcinoma, Non-Small Cell Lung
CPG 7909 Injection in Non-Small Cell Lung Cancer
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone.
- Trial name
- NCT00070629
- Testing
- CPG 7909, Chemotherapy
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 116 people
- Sponsor
- Pfizer
Ewing's Sarcoma
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
A two-part trial in patients with metastic Ewing's sarcoma. Participants in Part 1 will be randomized to receive either Vigil immunotherapy or gemcitabine and docetaxel with the objective of comparing the overall survival between…
- Trial name
- NCT02511132
- Testing
- Vigil, Temozolomide, Irinotecan
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gradalis, Inc.
Locally Advanced Lung Carcinoma
Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC
This Phase 1 trial aimed to determine the maximum tolerated fraction dose (MTD) of hypofractionated radiotherapy (hypo-RT) combined with concurrent chemotherapy and subsequent consolidation immune checkpoint inhibitors (cICI) for…
- Trial name
- NCT04951063
- Testing
- Hypofractionated radiotherapy, Concurrent chemotherapy, Consolidation immunotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase I trial to study the effectiveness of low-dose radiation therapy to the abdomen combined with docetaxel in treating patients who have recurrent or persistent advanced ovarian, peritoneal, or fallopian tube cancer.
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer
- Trial name
- NCT00066456
- Testing
- 3-Dimensional Conformal Radiation Therapy, Chemosensitization/Potentiation Therapy, Docetaxel
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gynecologic Oncology Group
Breast Cancer
Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer
After a core biopsy of the tumor is obtained, patients with locally advanced breast cancer are randomized to receive 4 cycles of full dose doxorubicin (75 mg/m2 e3w) or docetaxel (100 mg/m2 e3w).
- Trial name
- NCT00123929
- Testing
- docetaxel, doxorubicin
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Hospital San Carlos, Madrid
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.